These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 9544164)
1. In vitro antitumor activity of rebeccamycin analog (NSC# 655649) against pediatric solid tumors. Weitman S; Moore R; Barrera H; Cheung NK; Izbicka E; Von Hoff DD J Pediatr Hematol Oncol; 1998; 20(2):136-9. PubMed ID: 9544164 [TBL] [Abstract][Full Text] [Related]
2. MGI 114: augmentation of antitumor activity when combined with topotecan. Weitman S; Barrera H; Moore R; Gonzalez C; Marty J; Hilsenbeck S; MacDonald JR; Waters SJ; Von Hoff D J Pediatr Hematol Oncol; 2000; 22(4):306-14. PubMed ID: 10959900 [TBL] [Abstract][Full Text] [Related]
3. A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. Langevin AM; Bernstein M; Kuhn JG; Blaney SM; Ivy P; Sun J; Chen Z; Adamson PC; Pediatr Blood Cancer; 2008 Mar; 50(3):577-80. PubMed ID: 17610262 [TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. Tolcher AW; Eckhardt SG; Kuhn J; Hammond L; Weiss G; Rizzo J; Aylesworth C; Hidalgo M; Patnaik A; Schwartz G; Felton S; Campbell E; Rowinsky EK J Clin Oncol; 2001 Jun; 19(11):2937-47. PubMed ID: 11387367 [TBL] [Abstract][Full Text] [Related]
5. Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors: a pediatric oncology group study. Langevin AM; Weitman SD; Kuhn JG; Weintraub ST; Baruchel S; Furman W; Bernstein M; Blaney S; Vietti T; J Pediatr Hematol Oncol; 2003 Jul; 25(7):526-33. PubMed ID: 12847318 [TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days. Dowlati A; Hoppel CL; Ingalls ST; Majka S; Li X; Sedransk N; Spiro T; Gerson SL; Ivy P; Remick SC J Clin Oncol; 2001 Apr; 19(8):2309-18. PubMed ID: 11304785 [TBL] [Abstract][Full Text] [Related]
7. Initial testing of cisplatin by the pediatric preclinical testing program. Tajbakhsh M; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Maris JM; Keir ST; Wu J; Reynolds CP; Smith MA; Lock RB Pediatr Blood Cancer; 2008 May; 50(5):992-1000. PubMed ID: 17554786 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of a rapid tetrazolium-based colorimetric assay for selecting anticancer drugs. Chen CF; Hwang JM; Wu CH; Chen CS; Chen KY Zhonghua Yi Xue Za Zhi (Taipei); 1990 Jul; 46(1):7-16. PubMed ID: 2176928 [TBL] [Abstract][Full Text] [Related]
10. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998 [TBL] [Abstract][Full Text] [Related]
11. Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles. Long BH; Rose WC; Vyas DM; Matson JA; Forenza S Curr Med Chem Anticancer Agents; 2002 Mar; 2(2):255-66. PubMed ID: 12678746 [TBL] [Abstract][Full Text] [Related]
12. Assessment of antineoplastic agents by MTT assay: partial underestimation of antiproliferative properties. Sobottka SB; Berger MR Cancer Chemother Pharmacol; 1992; 30(5):385-93. PubMed ID: 1505077 [TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors. Ricart AD; Hammond LA; Kuhn JG; Takimoto CH; Goetz A; Forouzesh B; Forero L; Ochoa-Bayona JL; Berg K; Tolcher AW; Rowinsky EK Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8728-36. PubMed ID: 16361560 [TBL] [Abstract][Full Text] [Related]
14. A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Perez RP; Godwin AK; Handel LM; Hamilton TC Eur J Cancer; 1993; 29A(3):395-9. PubMed ID: 8398340 [TBL] [Abstract][Full Text] [Related]
15. 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of solid tumors in children. Finklestein JZ; Albo V; Ertel I; Hammond D Cancer Chemother Rep; 1975; 59(2 Pt 1):351-7. PubMed ID: 167936 [TBL] [Abstract][Full Text] [Related]
16. Test for chemotherapeutic sensitivity of cerebral gliomas: use of colorimetric MTT assay. Jordan JP; Hand CM; Markowitz RS; Black P J Neurooncol; 1992 Sep; 14(1):19-35. PubMed ID: 1335043 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. Knapp DW; Chan TC; Kuczek T; Reagan WJ; Park B Am J Vet Res; 1995 Jun; 56(6):801-5. PubMed ID: 7653891 [TBL] [Abstract][Full Text] [Related]
18. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. Avramis IA; Laug WE; Sausville EA; Avramis VI Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297 [TBL] [Abstract][Full Text] [Related]
19. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors. Zhang L; Marrano P; Kumar S; Leadley M; Elias E; Thorner P; Baruchel S Clin Cancer Res; 2013 Nov; 19(21):5972-83. PubMed ID: 23989978 [TBL] [Abstract][Full Text] [Related]
20. Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue. Bailly C; Qu X; Anizon F; Prudhomme M; Riou JF; Chaires JB Mol Pharmacol; 1999 Feb; 55(2):377-85. PubMed ID: 9927631 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]